Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
anti-PD-1 or anti-PD-L1
DRUG
2 trials
Sponsors
Shanghai Chest Hospital
, University Hospital, Montpellier
Conditions
Non Small Cell Lung Cancer
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Unknown Phase
Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB
NCT04197076
Shanghai Chest Hospital
Non Small Cell Lung Cancer
Start: 2019-02-25
End: 2024-12-31
Target: 200
Updated: 2022-07-29
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
Completed
NCT04609930
University Hospital, Montpellier
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Start: 2020-10-30
End: 2021-08-31
Updated: 2021-12-23
Related Papers
An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
Frontiers in Oncology
2023-08-16
1 citations
An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis
Frontiers in Immunology
2022-08-19
7 citations
[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
2021-04-01
5 citations